What is Neurocrine Biosciences's operating lease income - 2028 (lessor)?

Neurocrine Biosciences (NBIX) reported operating lease income - 2028 (lessor) of $3.50M in Q1 2026.

How has Neurocrine Biosciences's operating lease income - 2028 (lessor) changed year-over-year?

Neurocrine Biosciences's operating lease income - 2028 (lessor) decreased by 0.0% year-over-year, from $3.50M to $3.50M.

Non-Current Assets

Operating Lease Income - 2028 (Lessor)

Neurocrine Biosciences Operating Lease Income - 2028 (Lessor) remained flat by 0.0% to $3.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $3.50M to $3.50M.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

First reportedQ3 2023

Last reportedQ1 2026May 5, 2026

Metric ID: operating_lease_income_2028_lessor

Historical Data

8 periods

	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	$1.70M	$1.70M	$2.70M	$3.50M	$3.50M	$3.50M	$3.50M	$3.50M
QoQ Change	—	+0.0%	+58.8%	+29.6%	+0.0%	+0.0%	+0.0%	+0.0%
YoY Change	—	—	—	+105.9%	+105.9%	+29.6%	+0.0%	+0.0%

Range$1.70M – $3.50M

CAGR+51.1%

Avg YoY Growth+48.3%

Median YoY Growth+29.6%

Current Streak7+ quarters growth

Frequently Asked Questions

What is Neurocrine Biosciences's operating lease income - 2028 (lessor)?: Neurocrine Biosciences (NBIX) reported operating lease income - 2028 (lessor) of $3.50M in Q1 2026.
How has Neurocrine Biosciences's operating lease income - 2028 (lessor) changed year-over-year?: Neurocrine Biosciences's operating lease income - 2028 (lessor) decreased by 0.0% year-over-year, from $3.50M to $3.50M.